From 12 to 15 November took place the “The liver Meeting” organised by the American Association for the Study of Liver Diseases (AASLD). The mission of the association is to advance and disseminate the science and practice of hepatology, and to promote liver health.
This year, Biosfer Teslab, together with OWL Metabolomics, University of Medicine from Indiana and Zydus Therapeutics had the opportunity to present a poster entitled “Saroglitazar is Associated with Improved Arterial Contour and Cardiovascular Risk in Patients with NAFLD”.
Cardiometabolic diseases (CMD) are the leading cause of morbidity and mortality worldwide, and lipid accumulation and inflammation – in the arteries and liver – are the main underlying aetiological processes.
NAFLD / STEATOHEPATITIS (Metabolic Fatty Liver Disease) as an hepatic manifestation of the metabolic syndrome has received much attention due to the enormous population growth of type 2 diabetes (DM2) and obesity, not only in Western countries but worldwide.
For this purpose, the company Zidus Therapeutics has developed Saroglitazar, a drug, which has already been proven to be effective against ALT (alanine aminotransferase), liver fat and dyslipidaemia in patients with NAFLD/NASH. The evaluation of the effects of Saroglitazar on atherosclerotic processes and the individual’s Cardiovascular Risk, however, remained a challenge due to the complexity of working with many lipoprotein parameters (LPP) and the interaction between them.
Therefore, the effects of the drug on the lipoproteins that influence cardiovascular risk and their impact on trial participants were assessed globally by performing a lipid analysis using Liposcale test on several participants who had received placebo or different doses of Saroglitazar over a certain period of time.
The study showed that the administration of Saroglitazar did indeed reduce cardiovascular risk in patients with NAFLD.
